Diseases & Conditions
Grants & Contracts
News & Events
See the list of featured NIAID clinical trials below or view the complete list of NIAID studies recruiting participants on ClinicalTrials.gov.
We are studying the effects of GARDASIL 9 vaccination in people with ICL, which stands for idiopathic CD4 T cell lymphocytopenia. People with ICL get more human papillomavirus (HPV)-related diseases than people without ICL. HPV-related diseases include skin and genital warts and a variety of genital and anal precancerous lesions and cancers. These diseases are also more severe and harder to treat in people with ICL.
People infected with HIV take drugs called antiretrovirals to keep the amount of HIV in their bodies low as well as anticoagulants to treat or prevent blood clots. This study will help gain a better understanding of how antiretrovirals and oral anticoagulants interact with each other.
A small group of people who are HIV positive remain healthy for long periods of time without medications. These Long-Term Non-Progressors have properties within their immune systems that control the virus and can help researchers determine how their immune systems control HIV disease.
This study will look for the development of IRIS (Immune Reconstitution Inflammatory Syndrome), a condition that can happen in patients who are infected with HIV, after they begin treatment with antiretroviral therapy (ART).
The NIH is conducting a research study for people living with HIV and on HIV medications whose CD4 t-cell count is >100 but <350, with an undetectable HIV viral load.
Determining how the immune system of some patients is able to control HIV is felt to be a very important step for designing vaccines and therapies for HIV.
This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).
The purpose of the study is to test HIV vaccines to see if they are safe. It is not possible to get HIV through participating in the study. Vaccines are used to create resistance to a disease, or to prevent infection. The study vaccines will use a live adenovirus, the type of virus that typically causes cold symptoms. We hope that this adenovirus will help to stimulate an immune response against HIV.
In this study, we will look at whether rifapentine and isoniazid affect blood levels of a commonly used antiretroviral called tenofovir alafenamide, or TAF. The United States Food and Drug Administration (FDA) has approved rifapentine and isoniazid for treating TB.